Acute coronary syndrome without ST-segment elevation. Update guidelines;Sindromi coronariche acute senza sopraslivellamento del tratto ST. Attuali linee-guida

Recenti Progressi in Medicina

Volumn 93, Issue 10, 2002, Pages 515-522

  Plebani, Mario ^a   Zaninotto, Martina ^a   Agostoni, Angelo ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NONE   (Italy)

Author keywords

Acute coronary syndrome: risk stratification; Treatment; troponin

Indexed keywords

ACUTE DISEASE; ARTICLE; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; SYNDROME;

ACUTE DISEASE; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; PRACTICE GUIDELINES; SYNDROME;

EID: 0040672082     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Molinaro G, Rouleau JL, Adam A. Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiovascular therapeutics. Current Opinion Pharmacol 2002; 2: 131-41.
2. Schmaier AH. The plasma kallikrein-kinin system conterbalances the renin-angiotensin system. J Clin Invest 2002; 109: 1007-9.
3. Tschope C, Schultheiss HP, Walther T. Multiple interactions between the renin-angiotensir and the kallikrein-kinin systems: role of ACE inhibition and ATI receptor blockade. J. Cardiovasc Pharmacol 2002; 39: 478-87.
4. Corti F, Burnett JC Jr, Rouleau J, Ruschitszka F, Luscher TF. Vasopeptidase inhibitors. A new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-62.
5. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358: 1525-32.
6. Campbell DJ. The kallikrein-kinin system in humans. Clin Experim Pharmacol Physiol 2000; 18: 1060-5.
7. Sharma JN, Sharma J. Cardiovascular properties of kallikrein-kinin system. Current Med Res Opinion 2002; 18: 10-17.
8. Heitsch H. Non peptide antagonist and agonist of bradykinin B2 receptor. Current Medicinal Chemistry 2002; 9: 913-8.
9. Fujii M, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Bradykinin improves left ventricular diastolic function under long-term angiotensin converting enzyme inhibition in heart failure. Hypertension 2002; 30: 952-7.
10. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg H, Bartunek J, Hetzer R, RegitzZagrosck V. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation 2002; 105: 286-9.
11. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-ccnverting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol 2001; 37: 359-66.
12. Boix F. Vasopeptidase inhibitors: a bradykinin link. Lancet 2002; 359: 1157-8.
13. Bralet J, Schwartz JC. Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends in Pharmacol Sciences 2001; 22: 106-9.
14. Messerli F, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000; 356: 608-9.
15. Coats AJS. Omapatrilat. The ups and downs of an exciting but complicated new drug. Int J Cardiol 2000; 74: 1-3.
16. Rouleau J, Pfeffer M, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C. Block AJ for the IMPRESS Investigators. Lancet 2000; 356: 615-20.
17. Adam A, Cugno M, Molinaro G, Perez M, Lepage Y, Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002; 359: 2088-9.
18. Agostoni A, Cicardi M, Cugno M, Zingale LC, Gioffre D, Nussberger J. Angioedema due to angiotensin-converting enzymes inhibitors. Immunopharmacology 1999; 44: 21-5.
19. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Incidence, prevention and management. Drug Safety 2001; 24: 599-606.
20. Lefebvre J, Murphey LJ, Hartet TV, Shan RJ, Simmons WH, Brown N. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002; 39 (part 2): 460-4.
21. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, Adam A. Angiotensin converting enzyme inhibitor associated angioedema is characterized by a slower degradation of des-Arg9-bradykinin. J Pharmacol Exp Ther (in corso di stampa).